Boston Scientific expects Q4 2026 organic revenue to fall 3% to 1%, and adjusted EPS to $0.79 amid cyber pressure and EP/WATCHMAN (NYSE:BSX).

Seeking Alpha Markets · 28 Oct, 17:11 UTC · Source

More on Radar

Want to see every report in real time?

Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.